SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...
SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...
Compared with DPP-4 inhibitors, SGLT-2 inhibitors were linked to a lower risk for incidental Parkinson disease among older adults with type 2 diabetes. Use of sodium-glucose cotransporter-2 (SGLT-2) ...
In a recent large-scale retrospective cohort study published in the journal Primary Care Diabetes, researchers used a comprehensive (n = 10,465) database-derived dataset to evaluate the adherence and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback